An observational study in Lymphedema of Leg, sponsored by Chang Gung Memorial Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by Chang Gung Memorial Hospital · Observational
Background: In addition to antegrade anastomosis, retrograde anastomosis has been thought to offer further improvements after lymphaticovenous anastomosis (LVA) by bypassing the retrograde lymphatic flow. However, this concept has yet to be validated. The aim of this study was to determine the impacts on outcomes of performing both retrograde and antegrade anastomosis, as compared to antegrade-only anastomosis for treating lower limb lymphedema.
560 studies on the registry are indexed under Lymphedema; 135 are open to participants now.
This study's planned enrollment of 87 is below the median of 106 across 144 observational studies indexed under Lymphedema.
Browse Lymphedema studies →Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients (age > 18 years) with lower limb lymphedema patients were enrolled from March 2016 to December 2020.
Exclusion Criteria:
This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled.
Other: Antegrade and retrograde anastomoses · Other: Antegrade-only anastomoses
Patients who had received both antegrade and retrograde anastomoses.
Patients who had received antegrade-only anastomoses.
Magnetic resonance volumetry
Magnetic resonance volumetry was used for outcome assessments. The primary endpoint was the volume change at 6 months after LVA.
Time frame: 6 months after LVA
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital